to Block Cancer Growth & Proliferation
In normal, healthy development, cells divide rapidly and proliferate to form the tissues and organs of the human body. Once these cells terminally differentiate, they are committed to a particular cell state and lose the ability to proliferate.
Genetic alterations have the potential to promote tumorigenesis – the process by which normal cells transform into cancer cells. These alterations hijack normal development pathways, pushing cancer cells into an earlier, proliferative cell state – also known as a plastic state. They do this by blocking terminal differentiation, inducing dedifferentiation (reversing a cell’s state to a less specialized and earlier cell state) or inducing transdifferentiation (the conversion of one cell state to another cell state).
The plastic states of cancer cells are associated with the most aggressive, metastatic, and drug-resistant tumors. By targeting the drivers that lock cancer cells in an altered cell state, we can revert the tumor cells back to their normal cell state and inhibit their growth and proliferation.
for Rapid Drug Discovery & Development
We have built a proprietary platform called AURIGIN that we are leveraging for the rapid discovery and development of the next generation of targeted cancer therapies.
AURIGIN is a proprietary platform that integrates our developmental biology expertise with AI Machine Learning algorithms. It includes a database of single cell genomics data that allows it to compare normal cell states to cancer cell states. The power of AURIGIN is its ability to harnesses novel insights into tumor biology and generate validated targets, identify optimized model systems for early program de-risking, and identify biomarkers for effective patient selection.
for the Next Generation of Targeted Cancer Therapies
We are developing a portfolio that is the direct output of our AURIGIN platform. We have identified a set of priority targets and programs that represent first-in-class or best-in-class opportunities for both solid tumor cancers and hematological malignancies.
We have fostered a culture that encourages our team to be curious, to think strategically and creatively, and to push the limits of science. We honor diversity and individuality, and are united by a single commitment to serve the patients and families who need new treatments.
Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual Meeting
Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, today announced two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The Company highlighted the distinct ability of its AURIGIN™ platform to identify both cell state plasticity, the proliferative state in which cancer cells grow, and the causative gene targets. In a second poster, Auron shared preclinical data from its program targeting KAT2A/B, an AURIGIN-identified histone acetyltransferase driving small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), and acute myeloid leukemia (AML). These data led to the nomination of AUTX-703, an orally available and selective KAT2A/B degrader development candidate, for which Auron expects to file an IND in 2024.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
